Aurobindo Pharma Ltd.

Aurobindo Pharma experienced significant activity on February 17, 2025, with a notable gain, outperforming its sector. However, the stock remains below its moving averages across multiple time frames, suggesting potential long-term underperformance. Recent metrics indicate a slight decline over the past month compared to the broader market.

Aurobindo Pharma faced a significant decline on February 14, 2025, underperforming both its sector and the broader market. The stock reached an intraday low and has shown a downward trend over the past month, indicating ongoing challenges within the pharmaceutical industry and the company's market position.

Aurobindo Pharma experienced a notable rebound on February 13, 2025, gaining 4.07% after three days of decline. The stock reached an intraday high of Rs 1182.45 and demonstrated high volatility. Its current price exceeds the 5-day and 20-day moving averages, while remaining below longer-term averages.

Aurobindo Pharma's financial results for the quarter ending December 2024 show mixed performance, with the highest quarterly net sales in five quarters at Rs 7,978.52 crore. However, challenges include a low operating profit to interest ratio, rising interest costs, and declining profitability metrics, alongside an increased debt-equity ratio.

Aurobindo Pharma has experienced significant activity, with a notable rise in stock performance on February 5, 2025. The stock has shown consecutive gains over two days, outperforming its sector. However, it has faced challenges over the past month, reflecting volatility within the pharmaceuticals industry.

Aurobindo Pharma experienced a notable performance on February 4, 2025, reversing a three-day decline and outperforming its sector. The stock reached an intraday high, showing mixed signals in moving averages. Despite recent volatility, its one-day performance contrasted with the broader market, reflecting challenges over the past month.

Aurobindo Pharma experienced a notable performance on February 4, 2025, reversing a three-day decline and outperforming its sector. The stock reached an intraday high, showing mixed signals in moving averages. Despite recent volatility, its one-day performance contrasted with the broader market, reflecting challenges over the past month.

Aurobindo Pharma experienced a notable performance on February 4, 2025, reversing a three-day decline and outperforming its sector. The stock reached an intraday high, showing mixed signals in moving averages. Despite recent volatility, its one-day performance contrasted with the broader market, reflecting challenges over the past month.

Aurobindo Pharma has experienced notable activity, gaining 3.03% on January 30, 2025, and outperforming its sector. Despite recent gains, the stock has declined 8.34% over the past month and is trading below key moving averages, highlighting ongoing challenges in the Pharmaceuticals & Drugs industry.

Aurobindo Pharma's stock has declined for three consecutive days, totaling an 8.21% loss. The stock underperformed compared to the broader sector and is trading below its moving averages. Over the past month, it has decreased by 10.40%, while the Sensex fell by 3.69%.

Aurobindo Pharma's stock has declined for two consecutive days, totaling a 4.93% drop. The company has underperformed its sector and is trading below its moving averages. Over the past month, the stock has decreased by 7.80%, contrasting with a smaller decline in the Sensex.

Aurobindo Pharma has demonstrated significant activity, outperforming its sector and achieving notable intraday gains. Despite a recent decline over the past month, the stock's current price is above its 5-day moving average, indicating a mixed trend relative to longer-term averages in the pharmaceuticals industry.

Aurobindo Pharma reported a gain of 3.17% on January 23, 2025, outperforming its sector. The stock has shown consecutive gains over two days, reaching an intraday high of Rs 1229.6. Despite recent positive activity, it remains below several key moving averages and has declined over the past month.

Aurobindo Pharma has encountered significant challenges, experiencing its eighth consecutive day of losses and a total decline of 13.2%. The stock has shown high volatility, trading below key moving averages, and has underperformed its sector amid broader market declines. Its recent performance remains a focal point for investors.

Aurobindo Pharma has recently undergone a revision in its score, reflecting ongoing challenges in the market. The stock has faced a notable decline, underperforming its sector and trading below key moving averages. Despite this, it has been added to MarketsMOJO's list, indicating potential interest from analysts.

Aurobindo Pharma has recently experienced a revision in its score by MarketsMOJO, reflecting concerns over its financial performance and growth potential. Despite a notable increase in interest, the company's operating profit has stagnated, and its debt-equity ratio has reached a concerning level. Aurobindo Pharma has been added to MarketsMOJO's list, indicating ongoing scrutiny of its market position.

Aurobindo Pharma Ltd. has seen a revision in its score by MarketsMOJO, reflecting recent market dynamics. Despite fluctuations, the stock outperformed its sector and demonstrated resilience with a notable intraday high. The adjustment in evaluation highlights the company's mixed performance across various moving averages, indicating a cautious outlook.

Aurobindo Pharma has been added to MarketsMOJO's list following a revision in its score, reflecting recent market fluctuations. The stock showed resilience with a notable gain, outperforming its sector. Despite remaining below key moving averages, its performance indicates a positive shift in market sentiment amidst broader market trends.

Aurobindo Pharma has experienced a revision in its score, reflecting recent market challenges. The stock has faced a notable decline, underperforming against the Sensex and trading below key moving averages. Despite these setbacks, Aurobindo Pharma has been added to MarketsMOJO's list, indicating ongoing interest from investors.